289 related articles for article (PubMed ID: 30518651)
21. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
[TBL] [Abstract][Full Text] [Related]
23. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
Front Immunol; 2019; 10():756. PubMed ID: 31105689
[TBL] [Abstract][Full Text] [Related]
24. Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.
Chen YQ; Wohlbold TJ; Zheng NY; Huang M; Huang Y; Neu KE; Lee J; Wan H; Rojas KT; Kirkpatrick E; Henry C; Palm AE; Stamper CT; Lan LY; Topham DJ; Treanor J; Wrammert J; Ahmed R; Eichelberger MC; Georgiou G; Krammer F; Wilson PC
Cell; 2018 Apr; 173(2):417-429.e10. PubMed ID: 29625056
[TBL] [Abstract][Full Text] [Related]
25. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.
Park JK; Han A; Czajkowski L; Reed S; Athota R; Bristol T; Rosas LA; Cervantes-Medina A; Taubenberger JK; Memoli MJ
mBio; 2018 Jan; 9(1):. PubMed ID: 29362240
[TBL] [Abstract][Full Text] [Related]
27. Imprinted Anti-Hemagglutinin and Anti-Neuraminidase Antibody Responses after Childhood Infections of A(H1N1) and A(H1N1)pdm09 Influenza Viruses.
Daulagala P; Mann BR; Leung K; Lau EHY; Yung L; Lei R; Nizami SIN; Wu JT; Chiu SS; Daniels RS; Wu NC; Wentworth D; Peiris M; Yen HL
mBio; 2023 Jun; 14(3):e0008423. PubMed ID: 37070986
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.
Henry C; Palm AE; Utset HA; Huang M; Ho IY; Zheng NY; Fitzgerald T; Neu KE; Chen YQ; Krammer F; Treanor JJ; Sant AJ; Topham DJ; Wilson PC
J Virol; 2019 Nov; 93(21):. PubMed ID: 31434733
[TBL] [Abstract][Full Text] [Related]
29. Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.
Prachanronarong KL; Canale AS; Liu P; Somasundaran M; Hou S; Poh YP; Han T; Zhu Q; Renzette N; Zeldovich KB; Kowalik TF; Kurt-Yilmaz N; Jensen JD; Bolon DNA; Marasco WA; Finberg RW; Schiffer CA; Wang JP
J Virol; 2019 Jan; 93(2):. PubMed ID: 30381484
[TBL] [Abstract][Full Text] [Related]
30. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T
Front Immunol; 2020; 11():1207. PubMed ID: 32636840
[TBL] [Abstract][Full Text] [Related]
31. Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone.
Gao J; Wan H; Li X; Rakic Martinez M; Klenow L; Gao Y; Ye Z; Daniels R
PLoS Pathog; 2021 Apr; 17(4):e1009171. PubMed ID: 33872324
[TBL] [Abstract][Full Text] [Related]
32. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
[TBL] [Abstract][Full Text] [Related]
33. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
34. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
[TBL] [Abstract][Full Text] [Related]
35. An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice.
Kim EH; Han GY; Nguyen H
Viruses; 2017 Aug; 9(8):. PubMed ID: 28825679
[TBL] [Abstract][Full Text] [Related]
36. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.
Nachbagauer R; Choi A; Izikson R; Cox MM; Palese P; Krammer F
mBio; 2016 Jan; 7(1):e01996-15. PubMed ID: 26787832
[TBL] [Abstract][Full Text] [Related]
37. A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.
De Marco D; Clementi N; Mancini N; Solforosi L; Moreno GJ; Sun X; Tumpey TM; Gubareva LV; Mishin V; Clementi M; Burioni R
PLoS One; 2012; 7(4):e34415. PubMed ID: 22496802
[TBL] [Abstract][Full Text] [Related]
38. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.
Tsai C; Caillet C; Hu H; Zhou F; Ding H; Zhang G; Zhou B; Wang S; Lu S; Buchy P; Deubel V; Vogel FR; Zhou P
Vaccine; 2009 Nov; 27(48):6777-90. PubMed ID: 19732860
[TBL] [Abstract][Full Text] [Related]
39. A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.
Bliss CM; Freyn AW; Caniels TG; Leyva-Grado VH; Nachbagauer R; Sun W; Tan GS; Gillespie VL; McMahon M; Krammer F; Hill AVS; Palese P; Coughlan L
Mol Ther; 2022 May; 30(5):2024-2047. PubMed ID: 34999208
[TBL] [Abstract][Full Text] [Related]
40. Influenza A virus hemagglutinin specific antibodies interfere with virion neuraminidase activity via two distinct mechanisms.
Kosik I; Yewdell JW
Virology; 2017 Jan; 500():178-183. PubMed ID: 27825034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
